About Contact Us Careers
Sign In

Chronic Obstructive Pulmonary Disease Treatment Market - Top Companies and Manufacturers

  • Report ID: 5523
  • Published Date: Oct 22, 2024
  • Report Format: PDF, PPT

Companies Dominating the COPD Treatment Market

    • GlaxoSmithKline plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • Novartis International AG
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Merck & Co., Inc.
    • Sunovion Pharmaceuticals Inc.
    • Chiesi Farmaceutici S.p.A.
    • Circassia Pharmaceuticals plc
Browse Key Market Insights with Data Illustration:

In the News

  • AstraZeneca announced the acquisition of Caelum Biosciences, a US-based biotech developing novel medicines for chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). This acquisition strengthens AstraZeneca's respiratory franchise and broadens their pipeline with promising late-stage assets.
  • AstraZeneca and Merck announced a collaboration for a Phase 3 clinical trial evaluating Lynparza® (olaparib), a targeted therapy, in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer harboring BRCA mutations. This partnership seeks to expand treatment options for this aggressive cancer with limited therapeutic options.

Author Credits:  Radhika Pawar


  • Report ID: 5523
  • Published Date: Oct 22, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of chronic obstructive pulmonary disease treatment is estimated at USD 20.52 billion.

Chronic Obstructive Pulmonary Disease Treatment Market size was over USD 19.76 billion in 2024 and is poised to cross USD 36.35 billion by the end of 2037, growing at more than 4.8% CAGR during the forecast period i.e., between 2025-2037. Increasing demand for healthcare sector will drive the market growth.

Asia Pacific industry is set to hold largest revenue share of 39% by 2037, impelled by surge in governmental efforts in the region.

The major players in the market are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and others.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample